z-logo
open-access-imgOpen Access
Circulating sphingomyelins on estrogen receptor-positive and estrogen receptor-negative breast cancer-specific survival
Author(s) -
Charleen D. Adams
Publication year - 2020
Publication title -
breast cancer management
Language(s) - English
Resource type - Journals
eISSN - 1758-1931
pISSN - 1758-1923
DOI - 10.2217/bmt-2020-0002
Subject(s) - breast cancer , estrogen receptor , medicine , estrogen , sphingomyelin , cancer , oncology , mendelian randomization , endocrinology , lipoprotein , cholesterol , biology , biochemistry , genetic variants , genotype , gene
Aim: This study aims to determine whether a causal relationship exists between circulating sphingomyelins and breast cancer-specific survival, since, if one does, sphingomyelins could be studied as a therapeutic target in the management of breast cancer. Patients/materials & methods: Mendelian randomization is used here to investigate whether higher levels of circulating sphingomyelins impact breast cancer-specific survival for estrogen receptor-negative (ER–) and estrogen receptor-positive (ER+) patients. Results: The results suggest a null effect of sphingomyelins for ER– breast cancer-specific survival and a protective effect for ER+ breast cancer-specific survival. Sensitivity analyses implicate low-density lipoprotein cholesterol as a potential confounder. Conclusion: Future studies should replicate and triangulate the present findings with other methods and tease out the roles of sphingomyelins and low-density lipoprotein cholesterol on breast cancer-specific survival.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom